Adding tirzepatide to ixekizumab for psoriatic arthritis with weight concerns
Treatments studied
Part of Bones, joints & muscles, Hormones & metabolism, Skin clinical trials.
This study tests adding tirzepatide (a once-weekly injection for weight and diabetes) to your current treatment with ixekizumab for psoriatic arthritis. It may help with both joint symptoms and weight.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have active psoriatic arthritis (PsA) that a doctor has diagnosed.
- You have a BMI of 30 or more, or a BMI of 27 or more with a weight-related problem like high blood pressure or diabetes.
- You have been taking ixekizumab for about 3 months.
- You have never taken tirzepatide or similar medicines like Ozempic or Wegovy before.
- You do not have serious stomach or bowel issues, a history of pancreatitis, or certain thyroid conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding tirzepatide (a weight-loss and diabetes drug) to ixekizumab (a psoriasis treatment) helps people with moderate-to-severe psoriasis who are overweight or have obesity. It is for those already taking ixekizumab for about 3 months.
This trial tests the weight‑loss medication tirzepatide (Mounjaro) in people who are overweight or have obesity and have stable coronary artery disease. The goal is to see if tirzepatide can reduce dangerous fatty plaque in heart arteries.
This is an observational study tracking how tirzepatide affects joint and heart health over one year. Researchers will collect images, blood samples, and body composition measurements to understand whether tirzepatide helps with joint inflammation and related conditions.
This study tests whether adding a weight-loss medication (tirzepatide) to a biologic (ixekizumab) helps people with psoriatic arthritis and overweight or obesity. You will need to have biopsies of joint tissue and fat to see how the treatment affects inflammation.
This trial tests if tirzepatide, a weekly injection, can help people with type 1 diabetes who are also overweight or obese. The goal is to see if it improves blood sugar control and supports weight loss.
This trial tests a medicine called tirzepatide, given as an injection, to see if it can improve daily function and symptoms in people with a weak heart (heart failure with reduced ejection fraction) who also have obesity. Tirzepatide works on two natural hormones to help with weight and may also improve heart health.
Hear when a new Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.